2-[2-(1,3-Benzodioxol-5-yl)ethynyl]-6-methylpyridine | 710946-89-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 2-[2-(1,3-Benzodioxol-5-yl)ethynyl]-6-methylpyridine
• 英文别名: 2-[2-(1,3-benzodioxol-5-yl)ethynyl]-6-methylpyridine
• CAS: 710946-89-7
• 化学式: C₁₅H₁₁NO₂
• 分子量: 237.258
• InChiKey: ROMDZWULDDOIPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[2-(1,3-Benzodioxol-5-yl)ethynyl]-6-methylpyridine 在 叠氮基三甲基硅烷 、 四丁基碘化铵 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 4-[4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-[1,2,3]triazol-2-ylmethyl]-benzonitrile
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor

  摘要：

  A series of 2-pyridinyl-[1,2,3]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Compound 8d showed significant ALK5 inhibition (SBE-luciferase activity, 25%; p3TP-luciferase activity, 17%) at a concentration of 5 muM that is comparable to that of SB-431542 (SBE-luciferase activity, 21%; p3TP-luciferase activity, 12%), but weak p38alpha MAP kinase inhibition (13%) at a concentration of 10 muM that is much lower than that of SB-431542 (54%). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.024
• 作为产物：
  描述：

  1-(benzo[1,3]dioxol-5-yl)-2-(6-methylpyridin-2-yl)ethanone 在 三氟甲磺酸酐 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以70%的产率得到2-[2-(1,3-Benzodioxol-5-yl)ethynyl]-6-methylpyridine
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor

  摘要：

  A series of 2-pyridinyl-[1,2,3]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Compound 8d showed significant ALK5 inhibition (SBE-luciferase activity, 25%; p3TP-luciferase activity, 17%) at a concentration of 5 muM that is comparable to that of SB-431542 (SBE-luciferase activity, 21%; p3TP-luciferase activity, 12%), but weak p38alpha MAP kinase inhibition (13%) at a concentration of 10 muM that is much lower than that of SB-431542 (54%). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.024

文献信息

• Synthesis and receptor assay of aromatic–ethynyl–aromatic derivatives with potent mGluR5 antagonist activity
  作者：David Alagille、Ronald M. Baldwin、Bryan L. Roth、Jarda T. Wroblewski、Ewa Grajkowska、Gilles D. Tamagnan

  DOI：10.1016/j.bmc.2004.09.042

  日期：2005.1

  Noncompetitive antagonists of the human metabotropic glutamate receptor subtype 5 (mGluR5) have been implicated as potential therapeutics for the treatment of a variety of nervous system disorders, including pain, anxiety, and drug addiction. To discover novel noncompetitive antagonists to the mGluR5, we initiated an SAR study around the known lead compounds MPEP and M-MPEP. Our results pointed out the critical role of the para position of the two aromatic rings, which leads to inactive products and permitted the discovery of potent mGluR5 antagonists (e.g., 16, 25, 28, 34 IC50 = 13.5, 11.9, 21, 15nM, respectively). (C) 2004 Elsevier Ltd. All rights reserved.
• Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor
  作者：Dae-Kee Kim、Joonseop Kim、Hyun-Ju Park

  DOI：10.1016/j.bmcl.2004.03.024

  日期：2004.5

  A series of 2-pyridinyl-[1,2,3]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Compound 8d showed significant ALK5 inhibition (SBE-luciferase activity, 25%; p3TP-luciferase activity, 17%) at a concentration of 5 muM that is comparable to that of SB-431542 (SBE-luciferase activity, 21%; p3TP-luciferase activity, 12%), but weak p38alpha MAP kinase inhibition (13%) at a concentration of 10 muM that is much lower than that of SB-431542 (54%). (C) 2004 Elsevier Ltd. All rights reserved.